METHODS	Response and survival were correlated with the level of ERCC1 expression in 56 patients with advanced ( stage IIIb or IV ) NSCLC treated as part of a multicenter randomized trial with Gem 1250 mg/m ( 2 ) days 1 and 8 plus CDDP 100 mg/m ( 2 ) on day 1 every 3 weeks .\